Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

August 1, 2026

Conditions

Combined Hepatocellular Cholangiocarcinoma

Interventions

DRUG

gemcitabine ,oxaliplatin,anlotinib,Sintilimab

Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)

All Listed Sponsors

lead

Sichuan University

OTHER

NCT06033118 - Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC | Biotech Hunter | Biotech Hunter